Immunome, Inc. (IMNM)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Immunome’s loss per share missed expectations, with EPS of -$0.76 trailing the -$0.61 estimate by -$0.15, based on preliminary third fiscal quarter of 2026 results reported November 10, 2026. Net income was a loss of roughly $85.8 million, down -49.3% from a loss of about $57.5 million a year ago, alongside operating income of around -$90.4 million as the company continued investing across its oncology pipeline, including antibody-drug conjugate programs such as Varegacestat and IM-1021. Operating cash flow was negative at about $60.8 million. Compared with the year-ago period, EPS declined -16.9% from -$0.65. For the next period, consensus calls for EPS of -$0.64 on revenue of $153,846.00.
About Immunome, Inc.
Immunome, Inc. (NASDAQ: IMNM) is a Biotechnology company in the healthcare sector developing oncology therapeutics in the United States. The company is a small-cap drug developer focused on antibody-drug conjugates and related cancer programs, with Varegacestat, IM-1021, and other pipeline assets spanning clinical and preclinical stages.
Today's Snapshot
The day ended with IMNM 2.3% lower at 16.78, in line with a weaker sector. IMNM closed within 2.2% of its 52-week low of 16.41.
Trading Volume
Above 10d avg 1.4M
1.4M
vs S&P 500 Today
Underperforming Market
-2.07%
Updated: November 18, 2026 at 21:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$18.06 - $21.38Sell
- RSI (14)36.75Neutral
- Stochastic %K (14, 3, 3)4.85Buy
- MACD Level (12, 26)-0.61Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.